Published • loading... • Updated
Health: Saidal and Novo Nordisk Algeria Join Forces to Produce Innovative Treatments Against Diabetes.
Summary by Dzair World
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Saidal Group and Novo Nordisk Algeria signed a strategic partnership agreement in Algiers on Tuesday aimed at producing innovative treatments for type 2 diabetes and metabolic syndrome, according to a statement from the state-owned group. The signing ceremony took place in the presence of Saidal's Chairman and CEO, Mourad Belkhalfa, and Novo Nordisk Algeria's Managing Director, Amine Dahawi.
4th of July SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
